These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 22024360)

  • 21. Methionine oxidation in α-synuclein inhibits its propensity for ordered secondary structure.
    Ponzini E; De Palma A; Cerboni L; Natalello A; Rossi R; Moons R; Konijnenberg A; Narkiewicz J; Legname G; Sobott F; Mauri P; Santambrogio C; Grandori R
    J Biol Chem; 2019 Apr; 294(14):5657-5665. PubMed ID: 30755483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN
    J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.
    Uversky VN
    J Biomol Struct Dyn; 2003 Oct; 21(2):211-34. PubMed ID: 12956606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
    Bickle L; Hopwood JJ; Karageorgos L
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
    Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
    Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-translational modification of α-synuclein in Parkinson's disease.
    Barrett PJ; Timothy Greenamyre J
    Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death.
    Lee JT; Wheeler TC; Li L; Chin LS
    Hum Mol Genet; 2008 Mar; 17(6):906-17. PubMed ID: 18065497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
    Wales P; Pinho R; Lázaro DF; Outeiro TF
    J Parkinsons Dis; 2013; 3(4):415-59. PubMed ID: 24270242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The misfolding mystery: α-synuclein and the pathogenesis of Parkinson's disease.
    Negi S; Khurana N; Duggal N
    Neurochem Int; 2024 Jul; 177():105760. PubMed ID: 38723900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.
    Li X; Koudstaal W; Fletcher L; Costa M; van Winsen M; Siregar B; Inganäs H; Kim J; Keogh E; Macedo J; Holland T; Perry S; Bard F; Hoozemans JJ; Goudsmit J; Apetri A; Pascual G
    Acta Neuropathol; 2019 May; 137(5):825-836. PubMed ID: 30805666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced α-Synuclein Fibrillation and Cytotoxicity.
    Kumar S; Jangir DK; Kumar R; Kumari M; Bhavesh NS; Maiti TK
    ACS Chem Neurosci; 2018 Feb; 9(2):230-240. PubMed ID: 28841377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein misfolding and aggregation in Parkinson's disease.
    Tan JM; Wong ES; Lim KL
    Antioxid Redox Signal; 2009 Sep; 11(9):2119-34. PubMed ID: 19243238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of fibrillation process of alpha-synuclein at the initial stage.
    Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
    Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for a partially folded intermediate in alpha-synuclein fibril formation.
    Uversky VN; Li J; Fink AL
    J Biol Chem; 2001 Apr; 276(14):10737-44. PubMed ID: 11152691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formation of toxic oligomeric alpha-synuclein species in living cells.
    Outeiro TF; Putcha P; Tetzlaff JE; Spoelgen R; Koker M; Carvalho F; Hyman BT; McLean PJ
    PLoS One; 2008 Apr; 3(4):e1867. PubMed ID: 18382657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease.
    Kardani J; Sethi R; Roy I
    Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1454-1463. PubMed ID: 28167231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.